AIM： To study the inhibitory effects of Fuzheng Yiliuyin （Decoction for Suppressing Tumors by Strengthening the Body Resistance） in combination with chemotherapeutics on human gastric carcinoma cell strain. METHODS...AIM： To study the inhibitory effects of Fuzheng Yiliuyin （Decoction for Suppressing Tumors by Strengthening the Body Resistance） in combination with chemotherapeutics on human gastric carcinoma cell strain. METHODS： Fuzheng Yiliuyin （ZY） combined with various kinds of chemotherapeutics was put into two kinds of cultivated human gastric carcinoma cell strains, then its inhibitory effects on human gastric carcinoma cell strains were determind by the MTT method. Flow cytorneter was used to assay the apoptosis rate, and the ultrastructure of gastric carcinoma cells was observed under transmission electron microscope. RESULTS： Obvious apoptosis was seen in gastric carcinoma cells after treatment with ZY for 72 h. ZY and chemical drugs had synergistic inhibition effects on the cultivated gastric carcinoma cells, but the effects were different on various cell strains. The inhibitory effects of ZY could be strengthened by cytotoxic action and apoptosis. ZY combined with tluorouracil, etoposide and cisplatin （EFP） chemotherapeutics had better inhibitory effects on SGC-7901, while ZY combined with EFP or with DDP chemotherapeutics had better inhibitory effects than other drugs on MGC-803. CONCLUSION： ZY induces apoptosis and inhibits the growth of gastric carcinoma cells. ZY has the synergistic function of chemotherapeutics.展开更多
Gastrin and cyclooxygenase-2(COX-2) playimportant roles in the carcinogenesis and progression ofgastric cancer.However,it remains unknown whether the combination of cholecystokinin-2(CCK-2) receptor antagonist plus CO...Gastrin and cyclooxygenase-2(COX-2) playimportant roles in the carcinogenesis and progression ofgastric cancer.However,it remains unknown whether the combination of cholecystokinin-2(CCK-2) receptor antagonist plus COX-2 inhibitor exerts synergistic anti-tumor effects on human gastric cancer.Here,we demonstrated that the combination of AG-041R(a CCK-2 receptor antagonist) plus NS-398(a selective COX-2 inhibitor) treatment had synergistic effects on proliferation inhibition,apoptosis induction,down-regulation of Bcl-2 and up-regulation of Bax expression in MKN-45 cells.These results indicate that simultaneous targeting of CCK-2 receptor and COX-2 may inhibit gastric cancer development more effectively than targeting either molecule alone.(C)2008 Elsevier Ireland Ltd.All rights reserved.展开更多
目的探究1型单纯疱疹病毒(herpes simplex virus type 1,HSV-1)突变株M6感染人支气管上皮细胞(16HBE细胞)后对巨噬细胞介导的免疫反应的影响。方法用HSV-1感染16HBE细胞分析培养液中细胞因子的变化;将巨噬细胞与被HSV-1毒株感染的16HBE...目的探究1型单纯疱疹病毒(herpes simplex virus type 1,HSV-1)突变株M6感染人支气管上皮细胞(16HBE细胞)后对巨噬细胞介导的免疫反应的影响。方法用HSV-1感染16HBE细胞分析培养液中细胞因子的变化;将巨噬细胞与被HSV-1毒株感染的16HBE细胞的上清液共培养并通过尾静脉回输至小鼠体内,分别在第1、3、7、28、56、90天对小鼠淋巴结细胞因子表达水平、脾脏T细胞比例变化、小鼠中和抗体表达水平以及特异性T细胞反应进行检测。结果16HBE细胞被HSV-1突变株感染后,上清液中募集和激活巨噬细胞相关的细胞因子均较高水平表达但略低于野毒株组;尾静脉回输实验后,突变株组小鼠淋巴结炎症因子、趋化因子和T细胞的比例随时间发生了不同的变化,并引起了弱于野毒株组的体液免疫和强于野毒株组的特异性T细胞免疫反应,且仅极少数与野毒株组具有显著性差异(P<0.05)。结论16HBE细胞被HSV-1突变株M6感染后能够释放募集和激活巨噬细胞的细胞因子,使巨噬细胞携带HSV-1突变株的特异性活化信息,激活了宿主的免疫系统,诱导了宿主的体液免疫和细胞免疫。展开更多
INTRODUCTIONThe main component of a traditional Chinese drug 'Pishuang'. arsenic trioxide (As2O3), has obviously selective anti-tumor effect on human hepatocellular carcinoma (HCC)in both in vitro and in vivo ...INTRODUCTIONThe main component of a traditional Chinese drug 'Pishuang'. arsenic trioxide (As2O3), has obviously selective anti-tumor effect on human hepatocellular carcinoma (HCC)in both in vitro and in vivo studies[1-5]. Due to limited effectiveness when any anti-carcinogen is used alone and obviously increased toxicity when the dose is raised, there is no exception for As2O3. Furthermore, combined chemotherapy contributes to improve therapeutic effectiveness, disperse toxicity and surmount drug-resistance,in which the combination of traditional Chinese and modern medicine has more advantages and characteristics. As a result,we made an experimental study on anti-tumor effect of As2O3in combination with cisplantin (PDD) or doxorubicin (ADM)on HCC. to investigate the possibility of AS2O3 in combination with PDD or ADM and nature of interaction between them,and to provide experimental basis for clinical application.展开更多
基金Supported by TCM Administration Bureau of Shannxi Province,China, No. 199704
文摘AIM： To study the inhibitory effects of Fuzheng Yiliuyin （Decoction for Suppressing Tumors by Strengthening the Body Resistance） in combination with chemotherapeutics on human gastric carcinoma cell strain. METHODS： Fuzheng Yiliuyin （ZY） combined with various kinds of chemotherapeutics was put into two kinds of cultivated human gastric carcinoma cell strains, then its inhibitory effects on human gastric carcinoma cell strains were determind by the MTT method. Flow cytorneter was used to assay the apoptosis rate, and the ultrastructure of gastric carcinoma cells was observed under transmission electron microscope. RESULTS： Obvious apoptosis was seen in gastric carcinoma cells after treatment with ZY for 72 h. ZY and chemical drugs had synergistic inhibition effects on the cultivated gastric carcinoma cells, but the effects were different on various cell strains. The inhibitory effects of ZY could be strengthened by cytotoxic action and apoptosis. ZY combined with tluorouracil, etoposide and cisplatin （EFP） chemotherapeutics had better inhibitory effects on SGC-7901, while ZY combined with EFP or with DDP chemotherapeutics had better inhibitory effects than other drugs on MGC-803. CONCLUSION： ZY induces apoptosis and inhibits the growth of gastric carcinoma cells. ZY has the synergistic function of chemotherapeutics.
文摘Gastrin and cyclooxygenase-2(COX-2) playimportant roles in the carcinogenesis and progression ofgastric cancer.However,it remains unknown whether the combination of cholecystokinin-2(CCK-2) receptor antagonist plus COX-2 inhibitor exerts synergistic anti-tumor effects on human gastric cancer.Here,we demonstrated that the combination of AG-041R(a CCK-2 receptor antagonist) plus NS-398(a selective COX-2 inhibitor) treatment had synergistic effects on proliferation inhibition,apoptosis induction,down-regulation of Bcl-2 and up-regulation of Bax expression in MKN-45 cells.These results indicate that simultaneous targeting of CCK-2 receptor and COX-2 may inhibit gastric cancer development more effectively than targeting either molecule alone.(C)2008 Elsevier Ireland Ltd.All rights reserved.
文摘目的探究1型单纯疱疹病毒(herpes simplex virus type 1,HSV-1)突变株M6感染人支气管上皮细胞(16HBE细胞)后对巨噬细胞介导的免疫反应的影响。方法用HSV-1感染16HBE细胞分析培养液中细胞因子的变化;将巨噬细胞与被HSV-1毒株感染的16HBE细胞的上清液共培养并通过尾静脉回输至小鼠体内,分别在第1、3、7、28、56、90天对小鼠淋巴结细胞因子表达水平、脾脏T细胞比例变化、小鼠中和抗体表达水平以及特异性T细胞反应进行检测。结果16HBE细胞被HSV-1突变株感染后,上清液中募集和激活巨噬细胞相关的细胞因子均较高水平表达但略低于野毒株组;尾静脉回输实验后,突变株组小鼠淋巴结炎症因子、趋化因子和T细胞的比例随时间发生了不同的变化,并引起了弱于野毒株组的体液免疫和强于野毒株组的特异性T细胞免疫反应,且仅极少数与野毒株组具有显著性差异(P<0.05)。结论16HBE细胞被HSV-1突变株M6感染后能够释放募集和激活巨噬细胞的细胞因子,使巨噬细胞携带HSV-1突变株的特异性活化信息,激活了宿主的免疫系统,诱导了宿主的体液免疫和细胞免疫。
基金Supported by the Youth Science Grant of Jiangshu Province,No.BQ98048.
文摘INTRODUCTIONThe main component of a traditional Chinese drug 'Pishuang'. arsenic trioxide (As2O3), has obviously selective anti-tumor effect on human hepatocellular carcinoma (HCC)in both in vitro and in vivo studies[1-5]. Due to limited effectiveness when any anti-carcinogen is used alone and obviously increased toxicity when the dose is raised, there is no exception for As2O3. Furthermore, combined chemotherapy contributes to improve therapeutic effectiveness, disperse toxicity and surmount drug-resistance,in which the combination of traditional Chinese and modern medicine has more advantages and characteristics. As a result,we made an experimental study on anti-tumor effect of As2O3in combination with cisplantin (PDD) or doxorubicin (ADM)on HCC. to investigate the possibility of AS2O3 in combination with PDD or ADM and nature of interaction between them,and to provide experimental basis for clinical application.
基金This project was supported by Heilongjiang Province government natural science funds (No:D03-55) and Heilongjiang Province sanitary bureau scientific funds (No:2003-003)
